BIOMAT Database Logo BIOMAT Database Logo

Pharmacogenomics of hydroxyurea therapy and fetal hemoglobin levels in sickle cell anemia. 2022

Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Graduate Program in Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, 31270-901, Brazil.

UI MeSH Term Description Entries
D010597 Pharmacogenetics A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION). Pharmacogenomics
D005319 Fetal Hemoglobin The major component of hemoglobin in the fetus. This HEMOGLOBIN has two alpha and two gamma polypeptide subunits in comparison to normal adult hemoglobin, which has two alpha and two beta polypeptide subunits. Fetal hemoglobin concentrations can be elevated (usually above 0.5%) in children and adults affected by LEUKEMIA and several types of ANEMIA. Hemoglobin F,Hemoglobin, Fetal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000755 Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. Hemoglobin S Disease,HbS Disease,Sickle Cell Anemia,Sickle Cell Disease,Sickle Cell Disorders,Sickling Disorder Due to Hemoglobin S,Anemias, Sickle Cell,Cell Disease, Sickle,Cell Diseases, Sickle,Cell Disorder, Sickle,Cell Disorders, Sickle,Disease, Hemoglobin S,Hemoglobin S Diseases,Sickle Cell Anemias,Sickle Cell Diseases,Sickle Cell Disorder
D000986 Antisickling Agents Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions. Desickling Agents,Agents, Antisickling,Agents, Desickling

Related Publications

Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
August 1984, The Journal of clinical investigation,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Hydroxyurea increases fetal hemoglobin production in sickle cell anemia.
January 1984, Transactions of the Association of American Physicians,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Stimulation of fetal hemoglobin production by hydroxyurea in sickle cell anemia.
January 1989, Progress in clinical and biological research,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Genetic modulation of fetal hemoglobin in hydroxyurea-treated sickle cell anemia.
May 2017, American journal of hematology,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
January 2002, Blood,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
December 2007, The pharmacogenomics journal,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
February 1997, Blood,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
December 2017, American journal of hematology,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia.
January 1987, Blood,
Rahyssa Rodrigues Sales, and Bárbara Lisboa Nogueira, and Marcelo Rizzatti Luizon
Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
September 2008, American journal of hematology,
Copied contents to your clipboard!